OSSIO Receives Prestigious Frost & Sullivan New Product Innovation Award for its Breakthrough OSSIOfiberTM Intelligent Bone Regeneration Technology

Award recognizes company’s dedication to transforming the orthopedic
market through its first-of-kind bio-integrative bone fixation solution

WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., an orthopedic fixation company, announced today that its
OSSIOfiberTM Intelligent Bone Regeneration Technology
was the recipient of the 2019 Frost & Sullivan North America New Product
Innovation Award. The company received the prestigious award within the
market of bone regeneration fixation devices, having demonstrated
best-in-class qualities in unique areas including understanding demand,
nurturing the brand and differentiating from the competition.

“OSSIO’s bone regeneration fixation platform is a one-of-a-kind solution
that integrates technology and innovation to improve patient quality of
life,” said Sowmya Rajagopalan, Global Program Director at Frost &
Sullivan. “OSSIOfiberTM is the first fully
bio-integrative fixation device that does not compromise quality, as it
uses a fiber architecture that is initially twice as strong as
traditional non-metal materials typically used within fixation devices
and it incorporates naturally into the bone over time, eliminating the
need for hardware removal surgery. OSSIO is at the sweet spot of
innovative orthopedic design and its unique implant material offers a
myriad of opportunities for the global fixation market.”

The OSSIOfiberTM Bone Pin Family received 510(k)
market clearance
from the United States Food and Drug Administration
in January and launched its first product offering in May for use in the
foot and ankle segment for the treatment of forefoot conditions where
hardware removal surgeries are prevalent. Full commercialization and
availability of the innovative fixation device is set to occur in all
states in the third quarter of 2019.

Offering a new category of non-permanent fixation material, the OSSIOfiberTM
Intelligent Bone Regeneration Technology features a first of its
kind, proprietary bio-integrative material that provides stability and
secure bone fixation during the healing process and gradual integration
into the native anatomy without any adverse biologic response. Combining
unparalleled mechanical strength and natural tissue healing in a
non-permanent implant, the OSSIOfiberTM platform has
broad application across the spectrum of orthopedic fixation, with plans
to enter extremities, trauma, sports, reconstruction, pediatrics and
spine segments over the next few years.

“Our OSSIOfiberTM platform represents a major
step forward in orthopedic fixation, offering the first credible
replacement to permanent metal implants that delivers an unprecedented
combination of strength and true bio-integration,” said Brian Verrier,
CEO, OSSIO. “We are honored to receive the esteemed Frost & Sullivan New
Product Innovation Award, as it represents our unyielding commitment to
elevating the standard of care in orthopedic fixation by transforming
the patient experience.”

Frost & Sullivan Best Practices awards recognize companies in a variety
of regional and global markets for demonstrating outstanding achievement
and superior performance in areas such as leadership, technological
innovation, customer service and strategic product development. Industry
analysts compare market participants and measure performance through
in-depth interviews, analysis, and extensive secondary research to
identify best practices in the industry.

About OSSIOfiberTM Intelligent Bone
Regeneration Technology

Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber
Intelligent Bone Regeneration Technology is a first-of-its-kind implant
material stronger than cortical bone that leaves nothing permanent
behind. OSSIOfiberTM is engineered to provide the
strength required for functional fixation and allows for full
integration into the native anatomy without adverse biological response.
OSSIOfiber™ implants utilize existing reimbursement and surgical
techniques. The OSSIOfiberTM Bone Pin Family
represents the first of several regulatory approvals for the company and
is cleared for use in the United States for maintenance of alignment and
fixation of bone fractures, osteotomies, arthrodesis and bone grafts in
the presence of appropriate additional immobilization.


OSSIO is an orthopedic fixation company committed to transforming the
orthopedic experience for patients, physicians and payors. Founded in
2014, its vision is to provide the first credible replacement to metal
implants in the multi-billion-dollar global orthopedic fixation market
with its OSSIOfiberTM Intelligent Bone Regeneration
Technology. OSSIO’s development headquarters is located in Caesarea,
Israel, and its commercial headquarters is in Woburn, Massachusetts. For
more information on the company visit www.ossio.io.

Forward-looking statements contained herein are based on estimates and
assumptions of OSSIO management and are believed to be reasonable,
though they are inherently uncertain and difficult to predict.


W2O Group
Katherine Boes
[email protected]

error: Content is protected !!